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Background and Purpose: Larynx cancer represents one of the most frequently
diagnosed head and neck malignancies, which is most often confined to the glottic area.
The aim of this study was to report the oncological outcome and identify prognostic
factors in early-stage glottic squamous cell carcinoma treated with radiotherapy.
Material and Methods: Patients (n = 761) diagnosed and treated in 10 centers
between 1990 and 2015 were retrospectively analyzed. Probabilities of loco-regional
control (LRC) and overall survival (OS) were calculated and possible prognostic factors
were analyzed using Cox proportional hazards models.
Results: The median follow-up was 63 months (range: 2–243). Three hundred and
sixty-four, 148 and 249 patients had cT1a, cT1b, and cT2 stage I-II disease, respectively.
Five and 10-years LRC/OS rates in the whole cohort were 83/82% and 80/68%,
respectively. Three patients developed distant recurrences. In univariate analysis, male
sex (HR: 3.49; 95% CI: 1.47–11.37; p < 0.01), T2 vs. T1a (HR: 1.62; 95% CI: 1.08–2.43;
p = 0.02) and anterior commissure involvement (ACI) (HR: 1.66; 95% CI: 1.38–2.45; p
< 0.01) were associated with impaired LRC. In multivariate analysis, male sex (HR: 3.42;
95% CI: 1.44–11.17; p < 0.01) and ACI (HR: 1.51; 95% CI: 1.01–2.28; p = 0.047)
remained poor prognostic factors. No relation of treatment technique and biologically
equivalent dose (BED) to oncological outcome was identified except for higher BED10(L
= 25; T = 1) yielding better LRC in T1a tumors (p = 0.04) in univariate analyses.
Conclusion: Our results highlight the negative impact of ACI on tumor control. A
less-expected finding was the impact of sex on tumor control. Further research is needed
to validate its prognostic value and investigate any related biologic or behavioral factors,
which may be modified to improve oncologic outcome.
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INTRODUCTION
Laryngeal squamous cell carcinoma comprises around 25% of
all head and neck cancers (1). About 50–60% of the laryngeal
squamous cell carcinoma arise from the glottic region (2) and
over 80% of those patients present in an early UICC (Union
for International Cancer Control) stage (3). The larynx has
important roles in production of phonation, coordination of
swallowing and respiration. Therefore, the treatment aim of
laryngeal cancer is not only achieving maximum disease control,
but also preservation of organ function. In the absence of large
randomized studies providing a clear evidence for the best
strategy to treat early-stage glottic squamous cell carcinoma
(EGSCC), many retrospective studies reported comparable
control rates following radiotherapy (RT) or surgery. The 5-year
loco-regional control (LRC) following RT ranges from 80 to 95%
for T1 and 61–82% for the T2 cancer. Five year overall (OS)
rates in stage I and II are in the range of 89–100% and 60–100%,
respectively (4, 5).
The negative prognostic factors reported for EGSCC are
higher stage (6), anterior commissure involvement (ACI)
(7–11), anemia (12), continuation of smoking (13), and
protracted treatment time (14). Amongst these, the impact of
dose/fractionation has been extensively investigated. Multiple
randomized studies have demonstrated a benefit of shorter
treatment time, regardless of whether that goal was achieved
by means of acceleration or hypofractionation (15–19). Current
recommendation in the national guidelines is to treat EGSCC
with fraction sizes of 2Gy up to 66 (stage I) - 70Gy (stage II)
preferably in an accelerated schedule or with hypofractionation,
with fraction sizes such as 2.25Gy up to 63Gy (stage I) – 65.25Gy
(stage II) and 2.75Gy to a dose of 55Gy (20–23). On the other
hand, there are also published works with findings contradicting
with the above-mentioned information (24, 25). Furthermore,
there seem to be other factors such as sex, which were suggested
to influence tumor control (26, 27) and survival (28, 29).
The aim of this retrospective study was to assess the oncologic
outcome and its potentially influencing factors after RT of stage I
and II EGSCC in a multicenter setting with a sufficient follow-up.
MATERIALS AND METHODS
Approvals of institutional and regional review boards were
obtained. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. The charts of all
patients diagnosed and treated with EGSCC in 10 university and
teaching hospitals from three countries (Switzerland, Turkey and
United Kingdom) between 1990 and 2015 with histologically-
proven stage I and II invasive EGSCC were reviewed. All patients
underwent endoscopic examination of the upper airways under
general anesthesia. The diagnostic workup of the stage II tumors
was completed with a magnetic resonance imaging or computed
tomography of the neck, and computed tomography or X-ray of
the chest based on the year and institution. Imaging workup for
staging of T1 tumors was not standard in every site throughout
the years the patients were diagnosed. Previously treated (i.e.,
surgery or radiation) cases were excluded. Surgical excisions with
a failed aim of achieving clear margins (i.e., with an indication
of adjuvant radiotherapy) were also excluded. Excisional biopsies
with a diagnostic intent were allowed.
The centers were arbitrarily selected via personal
communication. Patient and disease characteristics, such as
age, sex, date of diagnosis (date of initial positive biopsy), tumor
stage, presence of ACI and treatment features, such as start and
end date of RT, dose/fractionation and treatment technique
were collected. Regarding follow-up, information about relapse,
mortality, incidence and localization of second primary cancer
(SPC) were obtained. Staging was revised according to the 8th
edition of UICC staging system (30). Information about RT
portals and target volumes, smoking, alcohol abuse, toxicity and
complications was not obtained.
RT was delivered using two-dimensional conventional or
three-dimensional conformal technique in the majority of the
cases, followed by an era of intensity modulated radiotherapy
(IMRT). The follow-up schedules and assessment measures of
toxicity were not standard among all centers.
Due to the expected heterogeneity in dose and fractionation
schedules among centers, two distinct biologically equivalent
dose (BED) models were generated by using the following
equation (31): BEDα/β = D(1 + d/(α/β)) – (OTT – L) x T [D:
total dose; d: dose per fraction; OTT: overall treatment time; L: time
lag; T: time factor]. Based on L and T published in the literature
(31–33), two biological scenarios were simulated: BED10(L= 25;
T = 1) and BED10(L = 28; T = 0.6). BED10(L = 25; T = 1)
corresponds to a rather aggressive tumor biology, by which the
accelerated repopulation starts after day 25, and afterwards the
daily loss of dose regarding tumor control probability is 1Gy. On
the other hand, BED10(L = 28; T = 0.6) refers to a relatively less
aggressive tumor biology, by which the accelerated repopulation
starts after day 28, and the daily loss of dose is 0.6 Gy.
All time-to-event intervals were calculated based on the date
of initial positive biopsy. The follow-up time was not censored at
a predefined time point. Kaplan-Meier curves and log-rank test
were used to depict and compare the variables regarding time-
to event endpoints, respectively. Univariate Cox’s proportional
hazards regression was used to evaluate possible prognostic
factors including age, sex, T stage, ACI, BED10 and treatment
modality for LRC. Variables yielding two-sided p < 0.1 were
used to build multivariate models. Backwards elimination was
used to identify potential independent factors. Statistical analyses
were performed with JMP (version 14.0 - SAS Institute GmbH,
Germany). The anonymized version of the data will be provided
upon reasonable personal request.
RESULTS
Seven hundred sixty-one patients from three countries were
diagnosed and treated at 10 institutions in a timeframe of
25 years. The median follow-up was 63 months (range: 2–
243). Table 1 summarizes the patient, disease and treatment
characteristics (details of treatment characteristics provided
in the Supplementary Materials 1, 2). The reasons for
discontinuing with follow-up varied from patient preference to
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TABLE 1 | Patient, disease, and treatment characteristics.
Characteristics Whole cohort
(n = 761)
Stage T1a
(n = 364/48%)
Stage T1b
(n = 148/19%)
Stage T2
(n = 249/33%)
Median age in years (range) 65 (33-97) 64 (35-97) 68 (38-96) 65 (33-95)
Gender
Male 685 (90%) 331 (91%) 130 (88%) 224 (90%)
Female 76 (10%) 33 (9%) 18 (12%) 25 (10%)
Anterior commissure involvement
Yes 414 (54%) 124 (34%) 119 (80%) 171 (69%)
No 347 (46%) 240 (66%) 29 (20%) 78 (31%)
Radiotherapy technique
2D-/3D-RT 604 (79%) 301 (83%) 117 (79%) 186 (75%)
IMRT 157 (21%) 63 (17%) 31 (21%) 63 (25%)
Median number of fractions (range) 34 (16-68) 34 (16-62) 34 (16-63) 35 (20-68)
Median fraction size in Gy (range) 2 (1.18–3.14) 2 (1.2–3.14) 2 (1.18–3.14) 2 (1.18–2.75)
Median total dose in Gy (range) 68 (50–81.6) 68 (50.24–78.12) 68 (50–78.3) 70 (55–81.6)
Median treatment time in days (range) 45 (21-80) 46 (21-80) 46 (22-60) 43 (25-70)
BED10(L = 25; T = 1) median in Gy (range) 61.4 (29-77) 60.1 (29-77) 61 (49-77) 64.6 (36.6–74.6)
BED10(L = 28; T = 0.6) median in Gy (range) 70.8 (52.8–83.4) 70.6 (52.8–83.4) 70.8 (64.8–81.6) 71.9 (54.2–79.8)
2D-RT, two-dimensional radiotherapy; 3D-RT, three-dimensional conformal radiotherapy; BED, biologically equivalent dose; IMRT, intensity-modulated radiotherapy; RT, radiotherapy.
outsourcing the follow-up controls to an external ear, nose and
throat specialist in some centers.
Loco-regional control (LRC) at 2, 5 and 10 years were 89,
83, and 80%, respectively. Overall survival (OS) at 2, 5, and 10
years were 93, 82, and 68%, respectively. Figure 1 shows the
Kaplan-Meier curves for OS and LRC in patients with T1a, T1b,
and T2 stage tumors. Figure 2 demonstrates the separation of
Kaplan-Meier curves for LRC based on ACI for each T stage.
Across all centers, the most frequently used fraction size was
2Gy (66%). In a decreasing order; conventional fractionation
(defined as> 1.8 and< 2.25Gy) (69%), hypofractionation (25%),
pure hyperfractionation (14) (5%) and partial hyperfractionation
(e.g., concomitant boost) (1%) was utilized. Two centers
used a single standard dose/fractionation schedule (2 and
2.75Gy, respectively), whereas the remaining centers used
various schedules (Supplementary Material 2). Concerning the
composite impact of dose, fractionation and overall treatment
time, Figures 3 and 4 demonstrate the LRC differences in each
stage based on their median BED10(L =2 5; T = 1) and BED10(L
= 28; T = 0.6), respectively. There was no significant difference
in LRC according to BED for either model except for higher
BED10(L = 25; T = 1) yielding better LRC in T1a tumors
(Figure 3A). Treatment technique, fraction size, total treatment
time and BED were not normally-distributed in the whole cohort
(Supplementary Material 1) and were heterogeneous among
and within the institutions (Supplementary Material 2).
The results of the uni- and multivariate Cox proportional
hazard models evaluating the potential prognostic value of
various parameters for LRC are provided in Table 2. Male
sex, T2 stage and ACI were associated with inferior LRC
according to the univariate analyses. Male sex and the presence
of ACI at the time of diagnosis were isolated as independent
risk factors in multivariate analysis. Although not initially
planned, based on these results, an exploratory analysis was
performed to test the possible contribution of sex and ACI
to OS. Neither male sex (HR: 1.62; 95% confidence interval
[CI]: 0.93–3.19; p = 0.94) nor the presence of ACI (HR:
1.03; 95% CI: 0.76–1.41; p = 0.84) influenced OS. Similarly,
no significant difference in median age in men and women
was observed according to Wilcoxon test (both 65 years, p
= 0.96).
Out of 761 of patients, 3 underwent total laryngectomy due to
organ dysfunction without any evidence of tumor persistence or
recurrence (two patients initially treated with 2Gy per fraction,
the other one with 2.25Gy per fraction). One hundred and
nineteen patients (16%) experienced a biopsy-proven recurrence
in a median time of 15 months (range: 4–148). Patterns of
tumor recurrence and subsequent treatments are provided in
Table 3. With a median follow-up of 32 months (range: 0–224)
after tumor recurrence, OS at 2 and 5 years after recurrence
were 67 and 60%, respectively. The 5-years OS after tumor
recurrence were 68%, 76% and 43% in patients who originally
had T1a, T1b, and T2 tumors, respectively (p < 0.02). The
exact T and N stages at the time of recurrence were not
obtained. Of the patients with tumor recurrence, 88% were
treated with curative intent, all (n = 104) of them in the
form of salvage surgery. Nine and 87 patients underwent partial
(information about the partial laryngectomy types not available)
and total laryngectomies, respectively. Adjuvant re-irradiation
was required in 14.4% of these cases. The 2- and 5-years OS
after salvage treatment were 75 and 67%, respectively. The 5-
years OS after salvage treatment of patients with the initially
T1a, T1b, and T2 tumors were 69, 84, and 56%, respectively (p
= 0.17). Detailed information about the types of salvage surgery
and related complications was not obtained. The 2- and 5-years
larynx preservation rates (i.e., death with intact larynx censored)
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FIGURE 1 | Overall Survival (A) and Loco-regional control (B) separated by T stage.
after initial diagnosis in T1a/1b/2 stages were 93/93/89% and
88/87/85%, respectively.
A total of 94 patients were diagnosed with metachronous
SPCs. Of those; 28, 61 and 5 had head and neck SPCs, non-
head and neck SPCs and both (synchronous), respectively. The
incidence of SPC in 2, 5, and 10 years was 4, 10, and 21%,
respectively. No association between fraction size and SPC
risk was found: hazard ratio (per change in regressor over
entire range): 1.48; 95% CI: 0.44–4.78; p = 0.52. Based on the
results regarding the impact of sex on LRC and the lack of
data about smoking and alcohol status, an exploratory analysis
was performed to look for any difference in SPC among men
and women, which may indirectly suggest a difference in the
exposure to habitual carcinogens. However, no difference was
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FIGURE 2 | Loco-regional control separated by anterior commissure involvement in each stage. ACI, anterior commissure involvement; Loco-regional control in Stage
T1a (A), in Stage T1b (B), and in Stage T2 (C).
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FIGURE 3 | Loco-regional control separated by median BED10(L = 25; T = 1). Loco-regional control in T1a (A), T1b (B), and T2 (C) tumors. Each stage subgroup is
dichotomized with its own median value: stage T1a: 60.1Gy; stage T1b: 61Gy; stage T2: 64.6Gy.
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FIGURE 4 | Loco-regional control separated by median BED10(L = 28; T = 0.6). Loco-regional control in T1a (A), T1b (B), and T2 (C) tumors. Each stage subgroup
is dichotomized with its own median value: stage T1a: 70.6Gy; stage T1b: 70.8Gy; stage T2: 71.93Gy.
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TABLE 2 | Uni- and multivariate Cox’s proportional hazard models for loco-regional control.
Univariate analyses Multivariate model
Variable HR (95% CI) p HR (95% CI) p
Age ≥ vs. < 65 years 0.96 (0.67–1.38) 0.83 — —
Male vs. female sex 3.49 (1.47–11.37) <0.01 3.42 (1.44–11.17) <0.01*
Stage
T1b vs. T1a 1.19 (0.71–1.94) 0.49 1.00 (0.59–1.68) 0.99
T2 vs. T1a 1.62 (1.08–2.43) 0.02 1.34 (0.87–2.08) 0.18
T2 vs. T1b 1.36 (0.83–2.27) 0.22 1.34 (0.82–2.25) 0.25
ACI yes vs. no 1.66 (1.38–2.45) <0.01 1.51 (1.01–2.28) 0.047*
IMRT vs. 2D-/3D-RT 0.84 (0.49–1.36) 0.49 – –
BED10(L = 25; T = 1) > vs. ≤ 61.4 0.94 (0.65–1.35) 0.73 – –
BED10(L = 28; T = 0.6) > vs. ≤ 70.8 1.37 (0.95–1.96) 0.09 1.23 (0.85–1.80) 0.27
2D-RT, two-dimensional radiotherapy; 3D-RT, three-dimensional conformal radiotherapy; ACI, anterior commissure involvement; BED, biologically equivalent dose; CI, confidence interval;
HR, hazard ratio; IMRT, intensity-modulated radiotherapy; L, time lag; RT, radiotherapy; T, time factor; *Remaining p < 0.01 after backwards elimination.
TABLE 3 | Patterns of recurrence and treatments.
Site of recurrence Stage T1a Stage T1b Stage T2
Total number of recurrences 47 (13%)* 23 (16%) 49 (20%)*
Local 40 (85%) 17 (74%) 35 (71%)
Isolated neck nodes 2 (4%) 3 (13%) 4 (8%)
Local + neck nodes 4 (9%) 3 (13%) 8 (16%)
Distant only 0 0 1 (2%)
Loco-regional + distant 1 (2%) 0 1 (2%)
Treatment of recurrence
Treatment with curative intent 45 (96%) 21 (91%) 38 (78%)
Salvage S 38 (81%) 17 (74%) 34 (69%)
Salvage S + RT 7 (15%) 4 (17%) 4 (8%)
Salvage laryngectomy within S ± RT 43 (96%) 18 (86%) 35 (92%)
Total laryngectomy within
laryngectomies (remaining cases
underwent partial laryngectomy)
37 (86%) 18 (100%) 32 (91%)
Palliative chemotherapy 1 (2%) 1 (4%) 4 (8%)
Palliative RT 0 0 1 (2%)
Best supportive care 1 (2%) 1 (4%) 3 (6%)
Unknown/lost to follow-up 0 0 3 (6%)
RT, radiotherapy; S, surgery; *Percentage of the crude recurrence rate within the
whole cohort.
observed (HR for SPC in men/women: 1.06; 95% CI: 0.56–2.27;
p= 0.87).
DISCUSSION
The main objective of this pooled analysis was to report the
outcome of stage I-II EGSCC patients treated at 10 university
and teaching hospitals with definitive RT, in order to determine
outcomes and identify possible prognostic factors. Our study
confirms that RT of EGSCC results in favorable LRC and OS
in line with the literature (4, 5). On multivariate analysis,
independent negative prognostic factors for LRC were ACI and
male sex, with the latter being a rather unexpected finding.
By contrast with other subsites of head and neck tumors
where male sex has been consistently associated with poorer
outcome, a survival advantage for male sex has been reported
in larynx cancer (34, 35). It has been speculated that this
might be due to differences in tumor localization with men
being significantly more affected by glottic tumors while women
presenting more often supraglottic cancers (36, 37). However,
the presence of significant sex differences in our cohort solely
composed of patients with glottic laryngeal cancer points to
other possible factors, such as different history and behaviors
of smoking and smoking cessation between men and women
at the time of diagnosis, as well as during and after the
treatment. On the other hand, as an indirect surrogate for
exposure to carcinogens, no difference in the SPC incidence
between men and women was observed. Still, we can not
directly rule out the possibility of such a difference. It is
also worth noting, that the OS and the distribution of age
were not significantly different among men and women in
our cohort.
In the EGSCC literature, the distribution of sex is nearly
always descriptively reported, whereas its possible prognostic
value is less frequently addressed. In two separate recent pooled
analyses of National Cancer Database (USA) (28, 29), male sex
was found to be a prognostic factor negatively influencing OS
in the multivariate Cox proportional hazards models, whereas
its impact for LRC was not investigated. In some studies male
sex was associated (38–40) with poor LRC while this was not
the case in others (10, 17, 18, 41–43), as based on univariate
analyses. To the best of our knowledge, there are only other
two retrospective studies, which reported on male sex as a
poor prognostic factor for LRC emerging from the multivariate
analysis (26, 27). In the age of biomarkers, sex as one of the most
obvious phenotypic features can be the elephant in the room (44).
In one way or another, it is important to further investigate this
finding. The possible impact of genetic and hormonal factors
on tumor control would expand our understanding of tumor
biology and treatment response. On the other hand, in case of
the lack of a direct causality between sex and oncologic outcome,
but the identification of confounding factors such as behavioral
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differences (e.g., smoking and alcohol) among men and women,
more emphasis would be given to modify these habits.
Some previous retrospective studies demonstrated that ACI
is a poor prognostic factor for RT outcome (7–11), but these
results are not consistent with the results of other studies
(24). Some authors pointed out the possible underdosage of
tumors with ACI close to the skin caused by the air-tissue
interface (43). In our series, the finding of impaired LRC
in the presence of ACI was reproduced. However, due to
the lack of information about treatment volumes and details
of treatment techniques, the underlying reason could not be
identified. The impact of ACI should be further investigated,
which may be integrated in the future staging algorithms and
treatment algorithms.
Altered fractionation with shorter overall treatment time
is known to be associated with better tumor control and
survival benefit in head and neck cancer (45–50). In the last
decade, three prospective randomized trials from Japan and
Korea addressed fractionation specifically in EGSCC (17, 18,
25), favoring moderate hypofractionation (2.25Gy), with disease
outcome superiority and logistic benefits. On the other hand,
contrary to what was expected, RTOG 9512 showed increased
toxicity and futility with hyperfractionation in T2 glottic larynx
cancer (19). Using accelerated RT, the results of the DAHANCA
6 trial showed a significant improvement in the loco-regional
control of EGSCC with a hazard ratio of 0.60 (95% CI: 0.41–
0.89) with a median follow-up of 14.5 years. There were no
significant differences in long term toxicity between accelerated
and normofractionated RT (16). Despite of the relatively large
sample size, such an impact on oncologic outcome could not be
reproduced in our cohort, probably due to the lack of normal
distribution of fraction size, treatment time and BED. The only
exception shown by the univariate log-rank test on the BED10(L
= 25; T = 1) model yielding higher LRC in T1a tumors.
Nevertheless, this may also be a result of multiple testing with
two models in three tumor stages.
High SPC rates in head and neck cancer patients is a major
problem. With each passing year, about 3% of the successfully
treated patients are expected to develop a SPC (51, 52). In
the SEER database analysis published by Rusthoven et al. (53),
a reduced incidence SPC within the head and neck region
was observed in patients treated with vs. without RT (hazard
ratio: 0.71, 95% CI: 0.65–0.79; p < 0.01). The difference was
still significant in laryngeal subsite on multivariate analysis.
The authors suggested that RT had a preventative effect on
transformation of the subclinical malignant foci. Our results
about SPC incidence are consistent with the literature. Due to the
lack of previously published data, we performed an exploratory
analysis on fraction size and the incidence of SPC, and could not
find any correlation at all. However, our median follow-up of 5
years is not long enough to observe any meaningful difference or
exclude the long-term possibility of increased incidence of SPC.
Moreover, the hypothesis regarding ablation of the premalignant
foci with RT may be invalid or less prominent in the IMRT era,
and if still present, this effect might be limited in the treatment
of EGSCC, where elective nodal irradiation is often omitted.
Data regarding the size of radiation portals, target volumes
and whether elective nodal irradiation was performed was not
collected in our pooled patient cohort.
Recent data suggests that IMRT may decrease the toxicity of
RT for larynx cancer (54), although the approach of treating the
whole larynx as a compartment is still widely used for EGSCC.
It is based on the traditional conventional field design, which
was established in an era where image guidance in RT was
poor. Another reason was the laryngeal displacement due to
swallowing movements during RT, which was later reported to
be not a serious concern (55, 56). A combination of IMRT and
modified target volumes (57) offers the potential to avoid the
unnecessary dose to the healthy laryngeal tissue and especially to
the carotid arteries (58, 59). With a newer technique developed
by the Rotterdam group, it is even possible to apply 58.08Gy in
16 fractions limited to the involved vocal cord with a significant
dose reduction in the vicinity (60). The clinical results indicate no
grade 3 toxicity, whereas the 2-year LRC and OS were 100% and
90%, respectively (61). When compared with a historical cohort,
which was treated to the whole larynx (66/2Gy), single vocal cord
irradiation yielded less grade ≥2 acute toxicity (17 vs. 66%, p <
0.01) and lower voice-handicap index scores in all follow-up visits
performed in regular short intervals until 18 months (p < 0.01).
Based on these results, our group is about to start with a multi-
center randomized phase III trial, which will compare voice
quality after single vocal cord irradiation vs. transoral CO2 laser
microsurgery in Tis and T1a N0 glottic cancer (NCT04057209).
The lack of a significant difference in OS between different
initial T stages after salvage treatment can be explained by the
patterns of recurrence. Most tumors recurred locally, which
can be often successfully salvaged by total laryngectomy. On
the other hand, the quality of life burden of such measures is
well-known (62).
Our present study has limitations owing to its retrospective
and multi-center nature, which predisposes the results to
potential bias. Most importantly, we were not able to report
on toxicity, smoking and alcohol consumption status due
to the lack of consistent data. The wide range of dose-
fractionations and techniques employed across 10 centers limits
the ability of this type of analysis to identify a superior
schedule, although our analysis did not detect differing outcomes
based upon BED calculations. Last but not least, it should be
noted that the heterogeneity of primary treatment preferences
among participating centers presumably have an inevitable
impact on the results. During the data acquisition in each
center, the patients treated with RT were not systematically
identified within the whole collective of patients (including
those treated with primary surgery), who were diagnosed
with EGSCC. Therefore, the quantification of the treatment
patterns, which would indicate the institutional preferences, is
not available.
CONCLUSIONS
The results of our series demonstrate a negative impact of ACI
on tumor control, indicating an additional prognostic value
of ACI involvement beyond the current UICC TNM staging
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system for EGSCC. The less-expected and intriguing finding
was the negative impact of male sex on tumor control. Further
research is required in order to elucidate the true role of sex
on oncological outcome in glottic laryngeal cancer or investigate
any related behavioral factors, which may be modified for better
oncologic outcome.
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